Preparation method of indometacin ester derivative
By using triflate sulfonate reaction with cesium fluoride in the preparation of indomethacin ester derivatives, the problem of difficulty in removing by-products and high toxicity of reaction reagents in the prior art is solved, and high efficiency and safety are achieved The synthesis process simplifies the process and improves the purity and safety of the drug.
Patent Information
- Application Number
- CN202411189481.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-28
AI Technical Summary
In the existing preparation methods for indomethacin ester derivatives, by-products are difficult to remove and the reaction reagents used have a risk of carcinogenicity, which affects the safety and purity of the drug.
The reaction of trifluoromethanesulfonate compounds and cesium fluoride in a specific solvent is used to form a phenyne intermediate through fluoride ions, and the carboxyoxy atoms of indomethacin are combined to directly obtain indomethacin derivatives. , the addition of condensants and metal catalysts is avoided, and the synthesis process is simplified.
The efficient, safe and simple preparation of indomethacin ester derivatives is achieved, the purity and safety of the product are improved, the residue of by-products is avoided, and a new synthetic pathway is provided.
Smart Images

Figure CN119080673A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for preparing an indomethacin derivative, in particular to a method for preparing an indomethacin ester derivative. Background Art
[0002] Indomethacin is a common nonsteroidal anti-inflammatory drug in clinical practice. Most of these drugs are nonspecific cyclooxygenase (COX) inhibitors, that is, they can inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Further studies have shown that the greater the inhibitory effect on COX-2, the more significant its anti-inflammatory and analgesic effects; the stronger the inhibitory effect on COX-1, the greater the adverse reactions (Drugs, 1997, 53, 563-582).
[0003] Existing studies have found that indomethacin ester derivatives obtained by esterifying the carboxylic acid group on indomethacin have a highly effective and specific inhibitory effect on COX-2 (Proc. Natl. Acad. Sci. USA 2000, 97, 925-930). Therefore, methods for preparing indomethacin ester derivatives have been reported one after another, mainly including the following two methods:
[0004]
[0005] Method (a) requires the addition of 1,3-dicyclohexylcarbocyanine (DCC) and 4-dimethylaminopyridine (DMAP) to promote the condensation of indomethacin with alcohol compounds. However, the biggest disadvantage of this type of reaction is that the byproduct dicyclohexylurea is difficult to completely remove by the commonly used purification method, which affects the purity of the product. Method (b) requires the use of hexamethylphosphoric acid triamide (HMPA), which is a potential carcinogen and can cause inflammation when in contact with the skin for 24 hours, posing a great safety hazard. Therefore, it is particularly important to develop a simple, safe and efficient method for preparing indomethacin ester derivatives. Summary of the invention
[0006] Purpose of the invention: The purpose of the present invention is to provide a method for preparing indomethacin ester derivatives to solve the problems of difficult removal of by-products and high toxicity of reaction reagents in existing preparation methods.
[0007] Technical solution: The method for preparing an indomethacin ester derivative of the present invention comprises the following steps:
[0008]
[0009] Wherein, R1 is selected from H, halogen, C 1-3 Alkyl, C 1-3Alkoxy, cycloalkane or aromatic hydrocarbon group; R2 is selected from H or halogen, TMS is a trimethylsilyl group, and OTf is a trifluoromethanesulfonate group.
[0010] The structural formula of compound III is as follows:
[0011]
[0012] Among them, R1 and R2 can be in any substitutable position of the benzene ring.
[0013] Preferably, the base is cesium fluoride, and the solvent is at least one of acetonitrile, chloroform, ethyl acetate, and tetrahydrofuran.
[0014] Preferably, the molar ratio of compound II to compound III is 1:1-2.
[0015] Preferably, the molar ratio of the compound II to the base is 1:1-3.
[0016] Preferably, the reaction conditions of compound II and compound III are 20-30° C. for 4-10 hours.
[0017] Preferably, after the reaction, the following steps are further included: washing the crude product with water, extracting with ethyl acetate, drying under reduced pressure, and then performing column chromatography separation and purification using ethyl acetate: petroleum ether in a volume ratio of 1:10-20 as an eluent.
[0018] Preferably, the concentration of the compound II in the solvent is 0.1-0.25 mol / L.
[0019] Preferably, the compound III is at least one of the following compounds:
[0020]
[0021] The compound I obtained from the above compound III is any one of the following:
[0022]
[0023] The preparation reaction mechanism of the present invention is as follows:
[0024]
[0025] 2-(Trimethylsilyl)phenyl trifluoromethanesulfonate compounds can leave the trimethylsilyl (-TMS) group and the trifluoromethanesulfonate (-OTf) group under the action of fluoride ions in cesium fluoride to generate a benzyne intermediate in situ, which is then captured by the carboxyl oxygen atom on indomethacin in the form of nucleophilic attack to finally obtain indomethacin ester derivatives.
[0026] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: The synthesis method of the present invention is simple, does not require the addition of an external condensing agent or a metal catalyst, and provides a new approach for the development of indomethacin ester derivatives. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The synthetic route of indomethacin ester derivatives is shown in FIG.
[0028] Figure 2 Schematic diagram of the reaction mechanism of the present invention;
[0029] Figure 3 The H NMR spectrum of the indomethacin ester derivative 3a prepared in Example 1;
[0030] Figure 4 The carbon NMR spectrum of the indomethacin ester derivative 3a prepared in Example 1;
[0031] Figure 5 The H NMR spectrum of the indomethacin ester derivative 3b prepared in Example 2;
[0032] Figure 6 The carbon NMR spectrum of the indomethacin ester derivative 3b prepared in Example 2;
[0033] Figure 7 This is the H NMR spectrum of the indomethacin ester derivative 3c prepared in Example 3;
[0034] Figure 8 The carbon NMR spectrum of the indomethacin ester derivative 3c prepared in Example 3;
[0035] Fig. 9 The H NMR spectrum of the indomethacin ester derivative 3d prepared in Example 4;
[0036] Fig.10 This is the carbon NMR spectrum of the indomethacin ester derivative 3d prepared in Example 4. DETAILED DESCRIPTION
[0037] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0038] Example 1: A method for preparing an indomethacin ester derivative 3a is as follows:
[0039]
[0040] Raw materials preparation:
[0041] Indomethacin, purity >99%, Shanghai Aladdin Biochemical Technology Co., Ltd.;
[0042] 2-(Trimethylsilyl)phenyl trifluoromethanesulfonate, purity>95%, Shanghai Adamas Reagent Co., Ltd.;
[0043] Specific synthesis process:
[0044] At room temperature, 1 mmol of indomethacin, 1.2 mmol of 2-(trimethylsilyl)phenyl trifluoromethanesulfonate and 2 mmol of cesium fluoride were reacted in 6 mL of anhydrous acetonitrile solvent for 5 hours to obtain a crude product of indomethacin ester derivatives; the prepared crude product of indomethacin ester derivatives was washed with water, extracted with ethyl acetate, dried under reduced pressure, and separated by column chromatography with a volume ratio of ethyl acetate: petroleum ether = 1:10 to obtain a white solid product, i.e., indomethacin ester derivative 3a, with a column chromatography yield of about 83%.
[0045] The product structure is 1 H NMR, 13 C NMR was used to determine the results, and the results are as follows:
[0046] 1 H NMR (400MHz, CDCl3) δ7.68(d,J=6.4Hz,2H),7.48(d,J=6.8Hz,2H),7.36(t,J=6.0Hz,2H),7.22(t,J=5.6Hz ,1H),7.07-7.05(m,3H),6.90(d,J=7.2Hz,1H),6.71-6.69(m,1H),3.91(s,2H),3.84(s,3H),2.46(s,3H);
[0047] 13 C NMR (100MHz, CDCl3) δ169.5,168.5,156.2,150.8,139.5,136.4,133.9,131.4,130. 9,130.6,129.6,129.3,126.1,121.5,115.2,112.2,112.0,101.3,55.9,30.7,13.6.
[0048] Example 2: A method for preparing an indomethacin ester derivative 3b is as follows:
[0049]
[0050] Raw materials preparation:
[0051] Indomethacin, purity >99%, Shanghai Aladdin Biochemical Technology Co., Ltd.;
[0052] 3-Methoxy-2-(trimethylsilyl)phenyl trifluoromethanesulfonate, purity>97%, Shanghai Adamas Reagent Co., Ltd.;
[0053] Specific synthesis process:
[0054] At room temperature, 1 mmol of indomethacin, 1.2 mmol of 3-methoxy-2-(trimethylsilyl)phenyl trifluoromethanesulfonate and 2 mmol of cesium fluoride were reacted in 6 mL of anhydrous acetonitrile solvent for 5 hours to obtain a crude product of indomethacin ester derivatives; the prepared crude product of indomethacin ester derivatives was washed with water, extracted with ethyl acetate, dried under reduced pressure, and separated by column chromatography with a volume ratio of ethyl acetate: petroleum ether = 1:10 to obtain a white solid product, i.e., indomethacin ester derivative 3b, with a column chromatography yield of about 72%.
[0055] The product structure is 1 H NMR, 13 C NMR was used to determine the results, and the results are as follows:
[0056] 1 H NMR (400MHz, CDCl3) δ7.67(d,J=8.4Hz,2H),7.47(d,J=8.4Hz,2H),7.25(t,J=8.0Hz,1H),7.06-7.05(m,1H),6.91-6.89(m,1H), 6.78-6.75(m,1H),6.71-6.68(m,1H),6.67-6.64(m,1H),6.62-6.61(m,1H),3.90(s,2H),3.84(s,3H),3.77(s,3H),2.45(s,3H);
[0057] 13 C NMR (100MHz, CDCl3) δ169.5,168.5,161.0,160.7,157.1,156.2,151.7,139.5,136.4,133.9,131.3,131.0,130.6,130 .2,130.0,129.3,115.2,113.7,112.1,112.0,111.8,107.9,107.6,106.3,101.6,101.3,55.9,55.6,55.3,30.7,13.6.
[0058] Example 3: A method for preparing an indomethacin ester derivative 3c is as follows:
[0059]
[0060] Raw materials preparation:
[0061] Indomethacin, purity >99%, Shanghai Aladdin Biochemical Technology Co., Ltd.;
[0062] 6-Methyl-2-(trimethylsilyl)phenyl trifluoromethanesulfonate, purity>94%, Shanghai Adamas Reagent Co., Ltd.;
[0063] Specific synthesis process:
[0064] At room temperature, 1 mmol of indomethacin, 1.2 mmol of 6-methyl-2-(trimethylsilyl)phenyl trifluoromethanesulfonate and 2 mmol of cesium fluoride were reacted in 6 mL of anhydrous acetonitrile solvent for 5 hours to obtain a crude product of indomethacin ester derivatives; the prepared crude product of indomethacin ester derivatives was washed with water, extracted with ethyl acetate, dried under reduced pressure, and separated by column chromatography with a volume ratio of ethyl acetate: petroleum ether = 1:20 to obtain a white solid product, i.e., indomethacin ester derivative 3c, with a column chromatography yield of about 78%.
[0065] The product structure is 1 H NMR, 13 C NMR was used to determine the results, and the results are as follows:
[0066] 1 H NMR (500MHz, CDCl3) δ7.68-7.65(m,4H),7.48-7.46(m,4H),7.19-7.11(m,5H),7.07-6.97(m,4H),6.91-6.84(m,3H ),6.70-6.68(m,2H),3.93-3.89(m,4H),3.84-3.83(m,6H),2.46-2.45(m,6H),2.33-2.04(m,6H); Representative peak of minor isomer, 1 HNMR(500MHz, CDCl3) of minor isomerδ2.33(s,1H),2.04(s,5H);
[0067] 13 C NMR (125MHz, CDCl3) δ169.6,169.2,168.4,156.3,150.8,149.4,139.8,139.5,136.3,134.0,131.3,131.2,131.0,130.6,130.0,12 9.3,127.1,126.9,126.3,122.1,121.9,118.5,115.2,112.3,112.2,112.0,111.9,101.3,55.8,30.7,30.5,21.4,16.1,13.6,13.5.
[0068] Example 4: A method for preparing an indomethacin ester derivative 3c is as follows:
[0069]
[0070] Raw materials preparation:
[0071] Indomethacin, purity >99%, Shanghai Aladdin Biochemical Technology Co., Ltd.;
[0072] 4,5-Difluoro-2-(trimethylsilyl)phenyl trifluoromethanesulfonate, purity>97%, Shanghai Bid Pharmaceutical Technology Co., Ltd.;
[0073] Specific synthesis process:
[0074] At room temperature, 1 mmol of indomethacin and 1.2 mmol of 4,5-difluoro-2-(trimethylsilyl)phenyl trifluoromethanesulfonate and 2 mmol of cesium fluoride were reacted in 6 mL of anhydrous acetonitrile solvent for 5 hours to obtain a crude product of indomethacin ester derivatives; the prepared crude product of indomethacin ester derivatives was washed with water, extracted with ethyl acetate, dried under reduced pressure, and separated by column chromatography with a volume ratio of ethyl acetate: petroleum ether = 1:10 to obtain a white solid product, i.e., indomethacin ester derivative 3d, with a column chromatography yield of about 88%.
[0075] The product structure is 1 H NMR, 13 C NMR was used to determine the results, and the results are as follows:
[0076] 1 H NMR (400MHz, CDCl3) δ7.67(d,J=8.4Hz,2H),7.47(d,J=8.0Hz,2H),7.16-7.10(m,1H),7.02-7.01(m,1H),6.98 -6.93(m,1H),6.89-6.87(m,1H),6.82-6.80(m,1H),6.71-6.68(m,1H),3.89(s,2H),3.83(s,3H),2.45(s,3H);
[0077] 13 C NMR (100MHz, CDCl3) δ169.0,168.4,156.3,151.4(d,J C-F =14.0Hz),149.6(d,J C-F =13.0Hz),148.9(d,J C-F =14.0Hz),147.2(d,J C-F =12.0Hz),146.3(dd,J C-F=8.0,3.0Hz),139.6,136.5,133.8,131.3,131.0,130.5,129.3,117.6,117.5,117.4,117.3,115.2,111.9,111.7,111.6,111.5,101.3,55.9,30.5,13.5。
Claims
1. A method for preparing an indomethacin ester derivative, characterized in that: The steps include: Wherein, R1 is selected from H, halogen, C 1-3 Alkyl, C 1-3 Alkoxy, cycloalkane or aromatic hydrocarbon group; R2 is selected from H or halogen, TMS is a trimethylsilyl group, and OTf is a trifluoromethanesulfonate group.
2. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The base is cesium fluoride, and the solvent is at least one of acetonitrile, chloroform, ethyl acetate and tetrahydrofuran.
3. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The molar ratio of compound II to compound III is 1:1-2.
4. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The molar ratio of the compound II to the base is 1:1-3.
5. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The reaction conditions of compound II and compound III are 20-30° C. and 4-10 hours.
6. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: After the reaction, the method further comprises the following steps: washing the crude product with water, extracting with ethyl acetate, drying under reduced pressure, and performing column chromatography separation and purification using ethyl acetate: petroleum ether in a volume ratio of 1:10-20 as an eluent.
7. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The concentration of the compound II in the solvent is 0.1-0.25 mol / L.
8. The method for preparing indomethacin ester derivatives according to claim 1, characterized in that: The compound III is at least one of the following compounds:
Citation Information
Patent Citations
Synthesis method of compound indometacin-feruloyl esterase
CN102219727A
IPF as well as preparation method and application thereof
CN106046343A
Indomethacin phenyl ester derivatives, their use, and compositions containing them
EP0080271A1
